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Summary. TFF-peptides (Le. TFF1, TFF2, TFF3; 
formerly P-domain peptides, trefoil factors) have been 
established as secretory products typical of the 
gastrointestinal tract. Their synthesis has recently been 
recognized in a number of mucin-producing epithelial 
cells, for example, of the respiratory tract, the salivary 
glands, the uterus and of the conjunctiva. They have a 
pivotal role in maintaining the surface integrity of these 
delicate epithelia as constituents of mucus gels as well as 
by their anti-apoptotic properties and their motogenic 
activity modulating cell migratory processes. The latter 
is important for rapid healing in particular of 
gastrointestinal and respiratory epithelia by a process 
termed "restitution". On the other hand, one of these 
peptides - namely TFF3 - has been detected as a new 
neuropeptide of the human hypothalamo-pituitary axis 
where it is synthesized in oxytocinergic neurons of the 
paraventricular and supraoptic nuclei. From there it is 
transported to the posterior pituitary where it is released 
into the blood stream. Synthesis of TFF-peptides also 
occurs pathologically as result to chronic infiammatory 
diseases, for example of the gastrointestinal tract. 
Aberrant synthesis of TFF-peptides is observed in many 
tumors. 
Key words: TFF-domain, Mucins, Epithelia, 
Restitution, Cell migration, Ulcer, Inflammatory bowel 
disease, Pituitary, Neuropeptide, Oxytocin, Respiratory 
tract, Uterus, Salivary glands, Conjunctiva, Goblet cells 
lntroductlon 
Three trefoil factor family (TFF)-peptides (formerly 
P-domain peptides or trefoil factors; Hoffmann and 
Hauser, 1993) are known in mammals including human, 
namely TFF1, TFF2 and TFF3 (Table 1). The present 
nomenclature is based upon an agreement at a 
Conférence Philippe Laudat (Wright et al., 1997). These 
peptides consist of one ( m 1  and TFF3) or two (TFF2) 
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TFF-domains. Remarkably, TFFl  and TFF3 form 
cysteine-bridged homodimers (Chinery et al., 1995; 
Chadwick et al., 1997; Kinoshita et al., 2000). 
Consequently, a pair of TFF-domains seems to represent 
the functional unit for TFF-peptides. 
Human TFFl (formerly pS2) via cDNA cloning of 
an estrogen-responsive gene from a breast cancer cell 
line was the first member of the family to be discovered 
(Masiakowski et al., 1982; Jakowlew et al., 1984). TFF2 
(formerly spasmolytic polypeptideISP) was detected 
almost coincidentally in porcine pancreas (Jorgensen et 
al., 1982; Thim et al., 1985; Rose et al., 1989); human 
TFF2 was characterized later (Tomasetto et al., 1990; 
Gott et al., 1996). The high similarity between TFFl and 
TFF2 was first recognized in the course of analyzing 
TFF-domains from the frog integumentary mucin FIM- 
A.l (formerly spasmolysin; Hoffmann, 1988). TFF3 
(previously called intestinal trefoil factor/iTF or hP1.B) 
from rat intestine was the third mammalian TFF-peptide 
described (Suemori et al., 1991) and its human homolog 
was reported in 1993 (Hauser et al., 1993; Podolslq et 
al., 1993). 
Al1 three human TFF-genes are clustered on 
chromosome 21q22.3 where TFFl, TFF2 and TFF3 are 
arranged head to tail (Chinery et al., 1996; Gott et al., 
1996; Hattori et al., 2000). 
The minimum consensus seauence for TFF-domains 
reads (Hoffmann and Hauser, 1993): 
C-%-7-R-X2-C-G-X8-C-X4-C-C-X,-W-C. 
The six conserved cysteine residues form 
intramolecular disulfide bridges, which are responsible 
for the remarkable protease resistance of TFF- eptides, 
are paired in the manner cl-6, c2-c4, c3-c8 (Thim 
1989; Kinoshita et al., 2000). The 3-D structures of 
porcine TFF2 (Carr, 1992; Gorman et al., 1992; Gajhede 
et al., 1992, 1993; Carr et al., 1994; De et al., 1994; 
Petersen et al., 1996) and the monomeric C58S mutant 
of human TFFl (Polshakov et al., 1995, 1997) revealed 
unusual molecular surface features such as a prominent 
hydrophobic patch. 
TFF-peptides have also been detected in amphibia 
(Table 1). The Xenopus laevis homolog of mammalian 
TFFl is xP1 (Hauser and Hoffmann, 1991; Hoffmann 
and Hauser, 1993) and the functional equivalent of 
mammalian TFF2 seems to be xP4.1 consisting of four 
Molecular medicine of TFF-peptides 
TFF-domains arranged in tandem (Hauser and 
Hoffmann, 1991; Jagla et al., 1998). The homolog of 
mammalian TFF3 is not known in X. laevis so far. The 
TFF-peptides xP4.2 (Botzler et al., 1999) and xP2 
(Hauser et al., 1992) in X. laevis were discovered in the 
gastrointestinal tract and the skin respectively, but 
mammalian homologs are missing. xP4.2, a result of a 
gene duplication in X. laevis, might be a semi-homolog 
of mammalian TFF2 which shows a clearly different 
expression pattern in the esophagus and stomach when 
compared with xP4.1 (Botzler et al., 1999). 
TFF-domains are also present in a variety of mosaic 
proteins. Human examples are zona pellucida proteins 
ZP1 and ZPB (Bork, 1993; Harris et al., 1994; Hughes 
and Barratt, 1999), as well as the human sugar degrading 
enzymes sucrase-isomaltase (Tomasetto et al., 1990), a- 
glucosidase (Hoefsloot et al., 1988) and maltase- 
glucoamylase (Nichols et al., 1998). 
Normal cellular locallzation of TFF-peptides 
Hoffmann, 1991; Hanby et al., 1993b). Gastric faveolae 
in humans are known for their expression and secretion 
of the secretory mucin MUC5AC (Audie et al., 1993; Ho 
et al., 1995). Furthermore, minor amounts of TFFl are 
detectable in human mucous neck cells (MNCs; Piggott 
et al., 1991; Hanby et al., 1999). TFFl  is also a 
constituent of the human gastric juice in a concentration 
range between 30 and 100 nglml (Rio et al., 1988). 
Another physiologically important location of TFFl 
is in the human conjunctiva (Fig. 2A), where goblet cells 
secrete this peptide together with the mucin MUC5AC 
as a constituent of the ocular mucus (Gipson and 
Inatomi, 1997; Langer et al., 1999). 
TFFl is also synthesized to some degree in human 
Brunner's glands, probably by the surface and upper duct 
cells but not in the acinar portion (Wright et al., 1990b; 
Hanby et al., 1993a; Khulusi et al., 1995). Minimal 
amounts of TFFl  mRNA are detectable in human 
salivary glands (Jagla et al., 1999; Devine et al., 2000) 
and the human respiratory tract (Wiede et al., 1999; dos 
Santos Silva et al., 2000). 
Mammalian TFF-peptides were originally detected 
as secretory products of the gut. Recently, a number of 
human mucous epithelia were identifíed as a production 
site of TFF3 in particular. In these organs TFF-peptides 
are always co-secreted with mucins in clearly defined 
cell-specific distribution patterns (Table 2). TFF-peptides 
are also formed in minor amounts in the human brain. 
The stomach typically secretes the highest 
proportion of human TFF2 (consisting of two TFF- 
TFF-peptides in mucous epithelia 
The stomach is the major source of mammalian 
TFFl as well as its amphibian homolog xP1. This was 
shown, for example, for human (Rio et al., 1988) and X. 
laevis (Hauser and Hoffmann, 1991). Gastric TFFlIxPl 
is localized within secretory granules of faveolae cells 
(Fig. l), i.e. the surface epithelial cells and the pits (Rio 
et al., 1988; Piggott et al., 1991; Hanby et al., 1993b; 
Jagla et al., 1998; Newton et al., 2000) where mRNA is 
also detected (Tomasetto et al., 1990; Hauser and 
Table l. Cornpilation of TFF-peptides detected in various mucous 
epiíhelia of rnarnrnals and X. laevis, respectwely. 
NAME ORlGlN NUMBER OF TYPICAL LOCALIZATION IN 
TFF-DOMAINS HUMAN AND X. LAEVIS 
EPlTHELlA 
TFFl rnarnmals 
TFF2 rnammals 
TFF3 mammals 
xP1 X laevis 
stomach, conjunctiva 
stornach, Brunner's glands 
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xP2 X. laevis 2 skin 
xP4.1 X. laevis 4 stornach 
xP4.2 X. leevis 4 esophagus, stornach/corpus 
Flg. 1. lrnrnunohistochemical localization of TFFl in human gastric 
faveolae. Staining is with a polyclonal TFFl antiserum (Novocastra, 
Newcastle) and immunofluorescence with Cy3-label; nuclei are 
counterstained with DAPI. Scale bar: 200 prn. 
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Flg. 2. Immunohistochemical localization of TFFl or TFF3 in human conjunctival goblet cells. Staining is with a monoclonal TFFl sewm (Zymed 
Laboratories, San Francisco) and immunofluorescence with Cy3-label (A) or with antiserum anti-rTFF3-1 and immunofluorescen~~ dith fluorescein 
label (B); nuclei are counterstained with DAPI. Scale bars: 50 pm. Reproduced from Langer et al. (1999) with permission of the Association for 
Research in Vision and Ophthalmology. 
domains; Tomasetto et al., 1990) or in X. laevis its 
presumable homolog xP4.1 (consisting of four TFF- 
domains; Hauser and Hoffmann, 1991). Porcine stomach 
secretes only small amounts of TFF2 (Thim et al., 1982). 
Gastric TFF21xP4.1 is predominantly released from 
MNCs and antral gland cells (Hanby et al., 1993b; Jagla 
et al., 1998). In human, these cells synthesize MUC6 as 
their major secretory mucin (Ho et al., 1995; Bartman et 
al., 1998). Only weak TFF21xP4.1 staining was obsewed 
at the gastric surface epithelium. Thus, TFFlIxPl and 
TFF21xP4.1 show complementary cellular localization 
patterns within the stomach. TFF2 is present in the 
human gastric juice at concentrations between 1 and 20 
&m1 (May et al., 2000). 
Species differences with respect to the synthesis of 
TFF2 in the pancreas are observed. For example, TFF2 
is not detectable in normal human pancreas (Welter et 
al., 1992; Ohshio et al., 2000) whereas acinar cells of the 
porcine pancreas are the major source of TFF2 in this 
species (Thim et al., 1982; Rasmussen et al., 1992). 
TFF2 is also expressed in human Brunner's gland 
duct epithelium (Wright et al., 1990b) and in Brunner's 
gland acini (Hanby et al., 1993a; Khulusi et al., 1995), 
which are known for their MUC6 synthesis (Ho et al., 
1995; Bartman et al., 1998). 
This peptide has a quite different localization pattern 
when compared with T F F l  and TFF2 because 
expression is very scarce in the human stomach (Hauser 
et al., 1993; May and Westley). However, TFF3 is 
detectable in a variety of other human mucous epithelia 
lacking TFFl and TFF2. A major source of TFF3 are 
human intestinal goblet cells (Hauser et al., 1993; 
Podolsky et al., 1993) which typically secrete the mucin 
MUC2 and MUC3 (Audie et al., 1993; Chang et al., 
1994). 
- * 
h . .  ;' 
. '. 
Flg. 3. Immunonistochemical localization of TFF3 in the hr 1 
endoce~ix. Staining of epithelial cells (A) and gland-like structure 1 
with antiserum anti-rTFF3-1 and immunofluorescence with Cy3-label; 
nuclei are counterstained with DAPI. Scale bars: 100pm. - ; 
TFF3 is also found in the human utem, where it is 
mainly released from the surface epithelium and gland- 
like structures of the endocewix (Fig. 3) but not from the 
endometrium (Hauser et al., 1993; Wiede et al., 2001). 
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Here, co-secretion with MUCSB probably occurs 
(Wickstrom et al., 1998). 
A further physiologically important site of TFF3 
production is the human respiratory tract (Wiede et al., 
1999; dos Santos Silva et al., 2000), where TFF3 is 
secreted predominantly by mucous cells of the 
submucosal glands (together with MUC5B; Fig. 4) but 
also to some extent by goblet cells (together with 
MUCSAC and MUC5B; Hovenberg et al., 1996; 
Wickstrom et al., 1998; Wiede et al., 1999). 
Human salivary glands represent another site of 
TFF3 synthesis (Fig. 5). Relatively large amounts of 
TFF3 are stored only within serous cells of human 
submandibular glands (Jagla et al., 1999). These cells are 
known for their MUC7 synthesis (Nielsen et al., 1996, 
1997). However, TFF3 mRNA is also detectable in 
human sublingual (Jagla et al., 1999; Devine et al., 2000) 
and in parotid glands as well as in minor mucous glands 
(Devine et al., 2000). In contrast to the immunohisto- 
chemical localization (Fig. 5), expression of TFF3 
mRNA has been reported to occur in mucous but not in 
serous acini of submandibular glands (Devine et al., 
2000). 
TFF3 is also a characteristic secretory product of 
human conjunctival goblet cells (Fig. 2B; Langer et al., 
1999). Together with TFFl and MUC5AC it is probably 
a constituent of the mucus layer of the eye's complex 
tear film and might contribute to its rheological 
properties. 
TFF-peptides in the brain 
TFFl and TFF2 
TFFl is widely distributed throughout the adult rat 
brain with pronounced expression in the hippocampus, 
frontal cortex and the cerebellum (Hirota et al., 1995). 
Expression of TFFl mRNA in the hippocampus reaches 
a maximum around birth when maturation occurs and 
then gradually decreases. Astrocytes, but not neurons, 
have been reported to represent the major site of 
hippocampal TFFl synthesis in newborn rats (Hirota et 
al., 1995). Expression of TFFl mRNA in cultured mouse 
astrocytes changed during the cell cycle (Hirota et al., 
1994b) and can be markedly induced by various 
cytokines (IL6, IL-7 and TNF-a; Hirota et al., 1994a). 
There are neither reports on localization studies of TFFl 
in human brain nor are there data published concerning 
'a#! 
S - ,  c.; \ 1 
Flg. 4. lmmunohlstochemical localization of TFF3 in submucosal glands of human bronchi. A. Staining of mucous cells using antiserum anti-rTFF3-1 
and immunofluorescence with Cy3-label; nuclei are counterstained with DAPI. B. Mucin staining of parallel section with PASIaician blue. Scale bars: 
1 O0 pm. 
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neural expression of TFF2. ventricle (Jagla et al., 2000). This obsewation would fit 
with a report claiming localization of TFF3 in human 
tanycytes lining the third ventricle (Griepentrog et al., 
1999). 
This peptide has been detected in magnocellular 
neurons of the rat and human hypothalamus (Fig. 6; 
Probst et al., 1995, 1996). The oxytocinergic neurons in 
the human paraventricular and supraoptic nuclei were 
shown to be the sole site of TFF3 synthesis in these 
nuclei; the distinct population of vasopressinergic 
neurons is completely devoid of TFF3 (Jagla et al., 
2000). Thus, TFF3 is a new neuropeptide of the 
hypothalamo-pituitary axis transported together with 
oxytocin to the neurohypophysis. TFF3 - but not TFFl 
or TFF2 - is stored here in relatively large amounts 
awaiting release into the blood stream. Noteworthy is the 
M, of TFF3 from the posterior pituitary as estimated 
from gel electrophoresis which appeared somewhat 
higher than corresponding material from the duodenum, 
probably due to an unknown posttranslational 
modification (Fig. 7). This may influence the stability of 
TFF3 in the blood. TFF3 is also detectable in human 
post mortem cerebrospinal fluid obtained from the third 
Pathological expresslon of TFF-peptldes 
Wounding response and inflammatory diseases 
Aberrant expression of TFF-peptides was widely 
obsewed during various chronic inflammatory diseases; 
for example in ileal Crohn's disease, in colon mucosa of 
patients with ulcerative colitis and in gallbladder during 
acute cholecystis (Rio et al., 1991), in the pancreas of 
patients with chronic pancreatitis (Wright, 1994; Ebert et 
al., 1999), in gastric glands during gastric ulcer disease 
(Hauser et al., 1993), in various types of metaplasia 
(Hanby et al., 1993a; Khulusi et al., 1995; Shaoul et al., 
2000), in different hyperplastic polyps (Hauser et al., 
1993; Hanby et al., 1993c; Nogueira et al., 1999) and in 
Barrett's oesophagus (Hanby et al., 1994; Labouvie et 
al., 1999). 
Furthermore, it was shown that expression of TFF- 
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peptides is a typical response after gastric mucosal 
damage in various rat models of experimental ulceration 
(Alison et al., 1995; Konturek et al., 1997, 1998). Here, 
an ordered sequence of gene expression including 
epidermal growth factor receptor (EGFR), c-met, EGF, 
transforming growth factor alpha (TGF-a) and 
hepatocyte growth factor (HGF) was observed (Wong et 
al., 2000); in particular, TFF2 was identified as an early 
gastric response gene whereas TFF3 was expressed later 
in response. In contrast, TFFl was expressed during the 
acute phase of acid-induced colitis in the rat rectum (Itoh 
et al., 1996). Expression of TFF-peptides was also 
induced in gastrointestinal tissues of embryonic mice 
after incisional wounds (Otto and Patel, 1999). 
The discovery that al1 three TFF-peptides are 
typically secreted by a specific gland-like structure 
termed the ulcer-associated cell line (UACL) was 
certainly a major hallmark (Wright et al., 1990a,b; 
Hauser et al., 1993). This mucin-secreting glandular 
structure appears during a variety of chronic 
inflammatory conditions and contains a clearly defined 
proliferative zone about two-thirds of the way up to the 
duct. It develops from stem cells, most commonly in the 
small intestine, particularly in Crohn's disease and 
duodenal ulcer disease. The UACL is thought to 
represent a natural repair kit which is activated after 
mucosal damage (Wright, 1998). It has also been 
detected in the colon, in pancreatic ducts in chronic 
pancreatitis, in gall bladder in chronic cholecystitis, in 
the fallopian tube in chronic salpingitis and in 
inflarnmatory nasal polypi (Wright, 1998). Interestingly, 
TFF-genes show different expression patterns within the 
UACL, i.e. TFFl in the upper ductular portion and 
surface cells, TFF2 (together with EGF) in the lower 
duct and acinar portion and TFF3 (together with TGF-a, 
lysozyme and neutral mucins) throughout the gland 
(Ahnen et al., 1994; Patel et al., 1994; Wright, 1998). 
Hyperplastic neuroendocrine cells adjacent to the 
UACL express significant amounts of TFFl (Wright et 
al., 1993). Noteworthy is that this leads to a release of 
TFFl into the immediate local circulation and not to a 
luminal co-secretion with mucins. 
Tumors 
Haphazard pathological expression of TFF-peptides 
has been observed in many epithelial tumors (Henry et 
al., 1991; Luqmani et al., 1992) including the breast (&o 
et al., 1987; Poulsom et al., 1997), oesophagus 
(Labouvie et al., 1999), stomach (Luqmani et al., 1989; 
Theisinger et al., 1991; Machado et al., 2000), biliary 
tract (Seitz et al., 1991; Welter et al., 1993), pancreas 
(Welter et al., 1992; Ohshio et al., 2000), colon (Welter 
et al., 1994; Taupin et al., 1996; Uchino et al., 1997; 
Hackel et al., 1998), lung (Higashiyama et al., 1994), 
ovary (Wysocki et al., 1990), endometrium (Koshiyama 
et al., 1997), cervix (Olatinwo et al., 1996), skin (Hanby 
et al., 1998) and various neuroendocrine tumors 
(Bonkoff et al., 1995; Wang et al., 1997,1998). 
A general prognostic value of aberrant TFF-peptide 
expression in tumors is under debate. For example, TF'F3 
is significantly up-regulated in colorectal carcinomas 
with a mucinous phenotype known to bear an especially 
poor prognosis (Taupin et al., 1996) whereas TFFl 
expression in breast cancer seems to be associated with a 
longer survival of the patients (Ribiereas et al., 1998; 
Balleine and Clarke, 1999). Besides aberrant expression, 
also somatic mutations and loss of heterozygosity, in 
particular of the TFFl gene, were detected in gastric 
adenoma and carcinoma (Park et al., 2000). This 
suggests that TFFl is a gastric-specific tumor-suppressor 
gene. 
Flg. 7. Detection of TFF3 in extracts of human duodenum (D) or 
posterior pituitary (PP) after SDS-polyacrylamide gel electrophoresis 
Flg. 6. lmmunohistochemical localization of TFF3 in human (15%) and subsequent Western blot analysis using affinity purified 
hypothalamus. Immunofluorescence of magnocellular neuron in the antiserum anti-hTFF3-2. Recombinant human TFF3 (kindly provided by 
paraventricular nucleus with antiserum anti-hTFF3-1 and fluorescein Dr. L. Thim) is used as a control. The molecular size standard is shown 
label; nuclei are counterstained with DAPI. Scale bar: 50pm. on the leít. 
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Biological effects of TFF-peptides 
Protective and healing effects in vivo 
There are numerous in vivo studies which clearly 
document positive effects of al1 three TFF-peptides on 
the repair of ulcerated areas in the gastrointestinal tract. 
Additionally, transgenic animals lacking TFFl or TFF3 
show abnormalities of these gastrointestinal mucosae. 
Subcutaneous infusion of dimeric TFFl (50 pg. 
kg-l.h-l) prevents indomethacin-induced gastric damage 
in rats by about 70%, whereas monomeric C58S mutant 
TFFl reduced injury by only about 30% (Marchbank et 
al., 1998). This protective effect of TFFl is in line with 
results from transgenic mice overexpressing TFFl in the 
jejunum, where the amount of jejunal damage caused by 
indomethacin was markedly reduced when compared to 
control animals (Playford et al., 1996). Transgenic mice 
lacking TFFl failed to develop a functional antral and 
pyloric gastric mucosa. Al1 TFFl(-1-) mice developed 
antropyloric adenoma, 30% of which progressed to 
carcinomas (Lefebvre et al., 1996). Noteworthy is that 
about 70% of these animals failed to express gastric 
TFF2 (but had normal pancreatic TFF2 synthesis) 
indicating coordinated expression of TFFl and TFFQ in 
the stomach as already suggested from their genomic 
analysis (Gott et al., 1996). 
Subcutaneous infusion of recombinant human TFF2 
(50 pg.kg-l.h-l) in rats was shown to reduce 
indomethacin- and restraint-induced gastric damage 
(Playford et al., 1995) as well as stress-induced 
ulcerations (Konturek et al., 1997) by about 50%. A 
tenfold higher subcutanous dose of 500 pg.kg-l.h-l 
human recombinant TFF2 does not further reduce 
indomethacin-induced damage (McKenzie et al., 1997). 
Oral administration of up to 200 pg.kg-l TFF2 had no 
effect (Playford et al., 1995); only significantly higher 
orallintragastric doses of TFF2 showed protective effects 
in the rat. For example, 5 mg of recombinant human 
TFF2 reduced indomethacin-induced gastric damage by 
about 40% and ethanol-induced gastric injury by about 
70% (Babyatsky et al., 1996). An oral dose of about 3 
mg recombinant human TFF2 protects rats against 
aspirin-induced gastric injury by about 70% (Cook et al., 
1998). A daily intrarectal application of 0.5 mg 
recombinant human TFF2 for five days reduced the 
inflammatory index by 50% in a rat model of 
dinitrobenzene sulfonic acid-induced colitis (Tran et al., 
1999). 
Porcine TFF2 was also able to prevent 
indomethacin-induced gastric damage in rats by 40% 
when infused subcutaneously (50 pg kgml.h-l; McKenzie 
et al., 1997). In another study, subcutaneous injection of 
porcine TFF2 (50 pg.kg-l three times a day) reduced 
indomethacin-induced gastric ulcers in rats by 38%; 
surprisingly, oral application of porcine TFF2 (2 mg per 
day in the drinking water) showed an even better 
protection by about a 62% decrease of ulcerated area 
(Poulsen et al., 1999). In contrast, strong aggravation of 
mercaptamine-induced duodenal ulcers was observed in 
rats after subcutanous as well as oral application of 
porcine TFF2 (Poulsen et al., 1999). 
5 mg oraliy applied recombinant rat TFF3, produced 
in yeast, reduced indomethacin-induced gastric damage 
in rats by about 60% and ethanol-induced gastric injury 
by more than 90% (Babyatsky et al., 1996). In contrast, 
subcutaneous infusion of recombinant rat TFF3 
produced in Escheria coli (150 pg.kg-l.h-l) had no 
protective effect in a rat model of indomethacin- and 
restraint-induced gastric damage; however, there was a 
dramatic reduction in the amount of gastric lesions by 
80% when TFF3 infusion was accompanied by infusion 
of human EGF (1 pg.kg-l.h-l; Chinery and Playford, 
1995). This implies a synergistic effect of TFF3 and 
EGF; infusion of EGF had no significant effect on its 
own. Further evidence for the protective effect of TFF3 
was obtained from transgenic mice lacking TFF3 which 
showed irnpaired mucosal healing. The othenvise trivial 
colonic injury induced by 2.5% dextran sodium sulfate is 
lethal in these animals; rectal application of recombinant 
TFF3 resulted in reconstitution of normal healing of 
acetic acid-induced lesions (Mashimo et al., 1996). 
Remarkably, these TFF3(-1-) animals showed reduced 
expression of gastric TFFl  and TFF2, once again 
demonstrating co-ordinated expression of the TFF- 
peptides in the stomach (Taupin et al., 1999). 
Taken together, there i s  strong evidence for 
protective and healing functions of TFF-peptides, at least 
in the gastrointestinal tract. Noteworthy is that systemic 
subcutaneous application of TFF-peptides to the 
basolateral side of the mucosa seems to be more 
effective than oral application in most studies. 
Action as motogens in in vitro models of restitution 
Rapid repair, particularly of the gastric and 
respiratory mucosae, is observed after superficial injury 
of these epithelia by a process temed "restitution" (Silen 
and Ito, 1985). This healing process starts within 
minutes after damage well before proliferation or 
extensive inflammatory processes occur and is defined 
by migration, for example, of gastric surface mucous 
cells to cover the denuded area (Lacy, 1988; Erjefalt et 
al., 1995). The TFF-peptide familiy was proposed to 
have a role in cell migratory processes because 
expression of TFF-peptides is rapidly up-regulated after 
wounding or during ulcerations. A classical in vitro 
model to investigate restitution is to monitor migration 
of cultured rat intestinal epithelial IEC-6 cells after in 
vitro wounding (McCormack et al., 1992). Since then 
positive motogenic effects have been documented for al1 
three TFF-peptides using various cell lines. 
Recombinant dimeric human TFFl (5x10-~  M) 
significantly increased migration of cultured HT29 cells 
on plastic dishes whereas the monomeric C58S mutant 
TFFl had no motogenic effect, even at much higher 
concentrations (Marchbank et al., 1998). 
A similar motogenic effect on the human colonic 
Molecular medicine of TFF-peptides 
carcinoma cell lines HT29 and LIM1215 was observed 
for recombinant human TFF2 at concentrations >lo-6 M 
(Playford et al., 1995; Wilson and Gibson, 1997). 
Furthermore, human recombinant glycosylated TFF2 
( 6 . 8 ~ 1 0 - ~  M) was reported to dramatically stimulate 
migration of HT29 cells through 8-pm pore poly- 
carbonate filters in a transwell motility assay (Efstathiou 
et al., 1999). Recombinant human TFF2 also enhanced 
repair of a wounded monolayer of IEC-6 cells (8.4x10-~ 
M TFF2; Dignass et al., 1994) and primary oxyntic 
cultures (Kato et al., 1999). 
Migration of HT29 cells on plastic dishes could also 
be enhanced by M recombinant TFF3 and a marked 
synergistic effect was reported with M EGF 
(Chinery and Playford, 1995). Recombinant human 
or rat TFF3 also significantly induced restitution 
of IEC-6 cells (7 .6x10-~ M TFF3; Dignass et al., 
1994), LIM1215 cells (3.4x10-~ M TFF3; Wilson and 
~ i b s ó n ,  1997) and primky oxyntic cultures (Kato et al., 
1999). 
1n line with the motogenic effect of TFF-peptides is 
the obsemation that transfection of an adenocarcinoma 
cell line with TFFl enhances dispersed growth in a 3-D 
collagen gel and reduces extracellular matrix deposition 
(Williams et al., 1996). A similar tendency to form 
smaller and more dispersed colonies in a 3-D collagen 
gel was re~orted for a colon carcinoma cell line stablv 
iansfectedwith a vector expressing TFF3 (Uchino et al:, 
2000). 
Effect on apoptosis 
5x10-~ M TFF;! reduced apoptosis of MCF-7 breast 
cancer cells by 30% after 19 days in culture (Lalani et 
al., 1999). Furthermore, a TFF3-expressing HT29 cell 
line was resistant to induced apoptosis, and exogenous 
TFF3 at a concentration of about 7.6x10-~ M protected 
HCT116 and IEC-6 cells from apoptosis (Taupin et al., 
2000). The anti-apoptotic effect required intact TFF3 
dimer and phosphorylation of the EGFR (Kinoshita et 
al., 2000). These results obtained in vitro are in line with 
the in vivo observation that TFF3(-1-) mice have 
increased intestinal apoptosis (Taupin et al., 2000). TFF3 
prevented also IEC-18 cells from apoptosis and induced 
activation of transcription factor NF-KB (Chen et al., 
2000). 
These results of clear anti-apoptotic effects of TFF2 
and TFF3 stand in direct contrast to the previous report 
of Efstathiou et al. (1998), who describe a detachment of 
HT29 cells and an increase in the number of apo totic 
10-8 M). 
6 nuclei after treatment with recombinant TFF3 (10- and 
Effect on nitric oxide synthesis 
Binding of a biotinylated TFF3 fusion protein was 
reported to increase the leve1 of type 11 nitric oxide (NO) 
synthase as well as the NO production in IEC-18 cells 
(Tan et al., 1999). 
The TFF-receptor problem and signaling cascades 
triggered by TFF-peptides 
There are no clear molecular cloning data published 
in the last 15 years unambigously describing TFF- 
receptors in spite of circumstantial evidence for their 
existence. Early studies reported that porcine TFF2 
bound to the small intestine of the rat inhibiting 
adenylate cyclase activity (Frandsen et al., 1986; 
Frandsen, 1988). Further binding sites were found in the 
gastric faveolar epithelium and colonic crypts of 
histological sections using a B-galactosidase-TFF3 
fusion protein (Chinery et al., 1993). TFF2 or TFF3 
cross-linked to rat jejunal membrane preparations led to 
the identification of a protein complex showing TFF3- 
stimulated tyrosine phosphorylation with a M, of about 
45,000 or 28,000 after reduction; in vitro auto- 
radiography of [lz~]-labeled TFF3 revealed binding to 
rat gastric mucous neck cells as well as jejunal and 
colonic crypts (Chinery and Cox, 1995a). Further in situ 
binding assays using a biotinylated TFF3 fusion protein 
also stained rat gastric mucous neck cells and small (but 
not large) intestinal crypt cells; ligand blotting showed 
that this TFF3 fusion protein bound to a glycosylated 
membrane protein from rat small intestine with a M, 
after reduction of about 50.000 (Tan et al., 1997). This 
size of a putative TFF3-receptor is similar to that 
claimed by Podolsky (1997). Binding sites on mucous 
neck cells and Paneth cells of the small intestine were 
also obsemed in vivo after intravenous administration of 
porcine [ l z ~ ] - ~ ~ ~  in rats (Poulsen et al., 1998); in this 
study, pyloric glands and Brunner's glands were also 
labeled. In recent studies a B-subunit of the fibronectin 
receptor and a transmembrane protein (M,: 224,000) 
with similarity to CRP-ductin/muclin/Ebnerin were 
characterized from porcine stomach due to their binding 
capacity of porcine TFF;! (Thirn and Mortz, 2000). Thus, 
the characterization of putative TFF-receptors is 
certainly more complex than expected and far away from 
being finished. 
However, there are numerous publications 
describing different signaling cascades triggered by 
TFF-peptides. M recombinant human dimeric TFF3 
was reported to decrease tyrosine phosphorylation of 
mitogen-activated protein (MAP) kinases ERK1/2 in 
IEC-6 cells within 1 minute; this ERK inhibition was 
claimed to be blocked by sodium orthovanadate (Kanai 
et al., 1998). This is in sharp contrast to a previous report 
which detected increased ERK phosphorylation by TFF3 
monomer in IEC-6 cells for the first time (Boxberger et 
al., 1998). Furthermore, 7 .6x10-~ M recombinant 
dimeric TFF3 (or alternatively 8.3x10-~ M recombinant 
TFF2) also stimulated phosphorylation of ERKl in 
KATO-111 cells; maximum activation occured 5 minutes 
after stimulation and could be inhibited by the protein 
kinase inhibitor genistein (Taupin et al., 1999). Later on, 
the TFF-induced phosphorylation of ERK1, which is 
thought to be triggered by the Ras/MEK pathway, was 
shown to parallel the motogenic effect and did not 
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require TFF3 dimerization (Kinoshita et al., 2000). Thus, 
the motogenic effect of TFF-peptides is perfectly in line 
with the well known fact that ERK phosphorylation is 
essential for cell  migration processes leading to 
phosphorylation of myosin light-chain kinase (Klemke et 
al., 1997). 
Surprisingly, the TFF-triggered ERK activation is 
accompanied often by phos horylation of the EGFR. For 4' example, TFF2 ( 8 . 3 ~ 1 0 -  M) or TFF3 M and 
7.6x10-~ M) caused transient EGFR phosphorylation in 
HT29, COS-1 or AGS cells (Liu et al., 1997; Taupin et 
al., 1999; Kinoshita et al., 2000). Al1 attempts, however, 
have failed to demonstrate direct binding of porcine 
TFF2 or human TFF3 to the EGFR (Otto et al., 1996; 
Taupin et al., 1999). The activation of the EGFR was 
shown recently not to be necessary for the motogenic 
activity of TFF3 (Kinoshita et al., 2000); but it could be 
responsible for the synergistic effect of EGF and TFF3 
on migration of HT29 cells in vitro and for protection in 
vivo (Chinery and Playford, 1995); it could also be the 
reason for the modulatory effect of TFF3 upon EGF 
responses on ion transport phenomena (Chinery and 
Cox, 1995b). 
Furthermore, TFF3 triggered phosphorylation of the 
EGFR is required to prevent p53-independent apoptosis 
in HT29 cells through a signaling pathway dependent on 
phosphatidylinositol-3-kinase (PI-3-K), and protein 
kinase B (PKB)/Akt inhibiting the cleavage of 
poly(ADP-ribose) polymerase (PARP; Taupin et al., 
2000). This EGFRJPI-3-K-dependent anti-apoptotic 
pathway was also activated by dimeric TFF3 in AGS 
cells after induction of p53-dependent apoptosis with 
etoposide; a mutant TFF3 not capable of dimer 
formation was inactive in protecting the cells from 
apoptosis (Taupin et al., 2000). Recently, Chen et al. 
(2000) reported on an anti-apoptopic effect of dimeric 
TFF3 for IEC-18 cells via an alternative signaling 
cascade requiring PI-3-K, PKB and activation of 
transcription factor NF-KB. 
Thus, TFF3 seems to have a complex function. On 
the one hand, a single TFF-domain is  capable of 
triggering migration processes by activating the MAPK 
pathway independently of the EGFR. On the other hand, 
dimeric TFF3 is required to inhibit apoptosis in an 
EGFR-dependent fashion (Kinoshita et al., 2000); 
phosphorylation of the EGFR by TFF3 probably occurs 
via transactivation or with the help of ada tor molecules. 
-9 The very high concentration of 10- M TFF3 was 
reported to induce a sustained tyrosine phosphorylation 
of B- and y-catenins in HT29 cells which follows a 
transient phosphorylation of the EGFR (maximum after 
about 10 seconds; Liu et al., 1997). Treatment of these 
cells with or M TFF3 for 24 hours reduced the 
levels of E-cadherin, a-catenin, B-catenin and the 
adenomatous polyposis coli (APC) gene product leading 
to a significant disturbance of cell  aggregation, 
detachment of cells from the substratum and 
translocation of APC from the cytoplasm to the nucleus 
with nucleolar accentuation; the down-regulation of 
APC, E-cadherin, a-catenin and í3-catenin could be 
inhibited by tyrphostin A25, an inhibitor of protein 
tyrosin kinases (Liu et al., 1997; Efstathiou et al., 1998). 
TFF3 thus seems to be capable of triggering protein 
tyrosine phosphorylation with involvement of the 
cadherin-catenin complex. Noteworthy is  that 
phosphorylation of í3-catenin is known to be strictly 
regulated during cell migration (Müller et al., 1999). 
This link to cell migration processes is further supported 
by the observation that E-cadherin is essential for the 
motogenic effect of TFF2 (Efstathiou et al., 1999). The 
nuclear translocation of APC was suggested to influence 
ribosomal RNA synthesis and mitosis (Neufeld and 
White, 1997; Deka et al., 1999). 
lnteraction with mucins and the rheology of mucus 
TFF-peptides are co-secreted with mucins and are 
intimate constitutents of mucus gels. It was postulated, 
as a consequence of this co-localization, that TFF- 
peptides interact with mucins as  "link-peptides" 
influencing the rheological properties of these complex 
viscous biopolymers (Hauser et al., 1993). The TFFl 
dimer was shown to be strongly associated with gastric 
mucins even after caesium chloride density gradient 
centrifugation in the presence of 6M guanidine 
hydrochloride (Newton et al., 2000). 
A direct interaction of T F F l  and cysteine-rich 
domains at the C-termini of mouse Muc2 and mouse 
MucSAC has been reported only recently (Tomasetto et 
al., 2000). These results are in contrast to previous 
1 TFFl Inlamctlonl 
D4 B C CK 
Flg. 8. Schematic representation of the C-termini of the vWF-type 
mucins MUC2, MUCSAC, MUC50. MUC6 (Buisine et al., 1998) and 
FIM-0.1 (Probst et al., 1990) and their possible interaction with TFFl 
based upon the report by Tomasetto et al. (2000). Cysteine-rich 
modules are hatched and domains homologous with vWF are indicated: 
D4-domain, 0-like domain, C-domain, and cysteine knot motif (CK). 
Highly O-glycosylated serinelthreonine-rich sequences are indicated by 
vertical bars. 
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suggestions that TFF-peptides might interact with the 
oligosaccharide moiety of mucins (Gajhede et al., 1993). 
Probably, both the B-like as well as the C-domains 
homologous with von Willebrand factor (vWF) are 
involved in the direct interaction with TFFl as illustrated 
in Fig. 8. The molecular function of the C-domain in 
vWF or mucins is not yet known. However, a deletion of 
the C1C2 region prevented secretion of vWF (Voorberg 
et al., 1991). A direct interaction of TFF-domains with 
the vWF-type mucins MUC6 and frog integumentary 
mucin FIM-B.1 cannot be expected based on the results 
of Tomasetto et al. (2000) because FIM-B.l contains 
only a truncated C-domain and no B-like domain and 
both the B-like domain and the C-domain are completely 
missing in MUC6 (Fig. 8). 
Whether TFF-peptides interact with mucins during 
the secretory pathway, influencing the proteolytic 
cleavage or oligomerization of certain mucins, is 
currently not known. The direct interaction of TFF- 
peptides and some vWF-type mucins however might 
explain preliminary observations that TFF-peptides 
change the rheological properties of mucous gels 
(Dignass et al., 1994). The report on specific TFF- 
peptidelmucin interactions by Tomasetto et al. (2000) is 
also a challenge to understand the molecular architecture 
of frog skin mucus consisting of the JFF-domain 
containing mucins FIM-A.1 and FIM-C.l as well as the 
vWF-type mucin FIM-B.l (Hoffmann, 1988; Hauser et 
al., 1990; Hauser and Hoffmann, 1992; Joba and 
Hoffmann, 1997). 
Behavioral effects 
Synthetic TFF3lmonomer was tested in two different 
models for behavioral effects after bilateral application 
into the basolateral nucleus of the rat amygdala 
(Schwarzberg et al., 1999). In passive avoidance tests 
maximal effects were observed about 1 day after TFF3 
application regardless of if a retrieval test or a 
consolidation test was performed. Surprisingly, 
application of a low dose (2x6 pg) decreased avoidance 
latency wheras a high dose (2x60 pg) increased 
avoidance latency. This bi-directional effect was also 
observed using the elevated plus-maze test, where the 
locomotor activity on the open arms was increased after 
Table 2. Predominant TFF-peptidelsecretory mucin combinations 
0 b ~ e ~ d  in various human mucin-producing cells. 
C E U  TFF-PEPTIDEIMUCIN 
Gastric surface cell 
Brunner's glands 
Gastric mucous neck cell 
Intestinal goblet cell 
Conjunctivai goblet cell 
Respiratory goblet cell 
Respiratory submucosal glands 
Endocervical epitheli cell 
Submandibular gland: serous cell 
TFFIIMUCSAC 
TFFl +TFF2/MUC6 
TFF2/MUc6 
TFF3lMUC2 
TFFl +TFF3/MUCSAC 
TFF3IMUCSAC+MUCSB 
TFF3lMUC5B 
TFF3lMUC5B 
TFF3lMUC7 
a low dose injection and decreased after a high-dose 
injection. Generally, the results of both tests can be 
explained by anxiolytic or anxiogenic effects after low 
dose or high dose TFF3 injections, respectively. 
Posslble physiological functions of TFF-peptides 
A key role of TFF-peptides for maintenance of the 
surface integrity of mucous epithelia is widely accepted 
now. However, this major role is probably realized at 
least in a complex threefold manner: as typical 
constituents of mucuos gels; by modulating cell 
migratory processes; and by regulating apoptosis. 
TFF-peptide interaction with mucins could influence 
the rheology of the delicate mucus; for example of the 
cervix and the respiratory tract as well as the tear film of 
the eye. This might be of significance to explain certain 
pathological conditions (e.g. of the respiratory tract) 
where rheological properties of mucus are changed. A 
first hint for the precise regulation of the rheology of 
these viscous biopolymers might be the fact that each of 
the mucous epithelia secretes its own characteristic 
mucidi'FF-peptide combination (Table 2) which meets 
optimally the physiological needs of the specific 
epithelium. Furthermore, TFF-peptides could be 
involved in the interaction of microbia; in particular with 
gastric or respiratory mucus as well as with saliva. For 
example, Helicobacter pylori co-localizes with 
MUCSAC but not with MUC6 in the human stomach 
(Van den Brink et al., 2000); this is remarkable because 
only MUCSAC is expected to interact with TFFl (see 
above). Interaction of TFF-peptides with mucins appears 
to influence proton permeation through gastric mucus as 
reported for TFF2 (Tanaka et al., 1997). 
Furthermore, TFF-peptides are candidates for 
supporting mucosal integrity by triggering anti-apototic 
effects. This would be of particular benefit after mucosal 
damage. However, this role would probably depend on 
specific TFF-receptors. 
The concept of a protective role of TFF-peptides by 
promoting restitution is strongly supported by in vitro 
cell migration experiments. This motogenic effect 
probably also requires specific TFF-receptors and could 
be triggered by the MAPK signaling cascade; there are 
some indications for a synergistic effect with EGF. TFF- 
receptors are expected to be located at the basolateral 
side of the mucosae; for exarnple of the gastrointestinal 
and the respiratory tracts, because subcutaneous 
application of TFF-peptides in vivo is far more effective 
than oral application. This basolateral localization would 
be in line with that found for the EGFR (Wong and 
Wright, 1999). However, the question arises about the 
origin of basolateral TFF-peptides. TFF-peptides from 
mucous epithelia under physiological conditions are 
secreted apically towards the lumen; they can possibly 
reach the basolateral side only after mucosal damage. 
Thus, TFF-peptides could act as luminal surveillance 
peptides but without function unless mucosal damage 
has occured. The one physiological source capable of 
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releasing a TFF-peptide directly into the blood stream is 
the posterior pituitary from which oxytocinergic neurons 
secrete TFF3 (Jagla et al., 2000). A pulsatile secretion 
during sexual activity, parturation and suckling can be 
expected as well as a continuous release even in males, 
peaking at night in analogy to the release of oxytocin 
(Carter, 1992; Forsling et al., 1998). This would imply 
that restitution of mucous epithelia might also be a 
neurally-regulated process. This is still speculation. 
The discovery of rninute amounts of TFF-peptides in 
the brain is compatible with a potential role as a 
neurotransmitter/modulator, hormone or neurotrophic 
factor particularly during development. Al1 these 
neuropeptide functions however require the presence of 
TFF-receptors. TFF3 in particular produced in 
oxytocinergic neurons of the human hypothalamus 
(Jagla et al., 2000) is the most likely candidate for acting 
as a neurotransmitter/modulator in various brain regions 
innervated by these neurons, e.g. the brain stem, spinal 
cord and the pontine tegmentum. Specific oxytocinergic 
neurons of the paraventricular nucleus are also 
considered to be putative satiety neurons for eating 
behavior. Intrahypothalamic release of TFF3 might also 
be responsible for morphological plasticity of the 
hypothalamic nuclei. Extrahypothalamic pathways 
connecting the hypothalamus and the limbic system in 
the rat might explain the fear-modulating action of TFF3 
(Schwarzberg et al., 1999). Furthermore, the release of 
TFF3 from the posterior pituitary into the blood stream 
opens the question of its peripheral target organs. 
Additional physiological functions other than enhancing 
surface integrity of mucous epithelia will be of major 
interest. 
Taken together, the motogenic and anti-apoptotic 
actions of TFF-peptides as well as the minute neurona1 
secretion particularly of TFF3 favour the existence of 
specific TFF-receptors. Their molecular characterization 
revealing the signaling cascades triggered by TFF- 
peptides will be the major goal for the future in order to 
eventually understand the molecular function of this still 
enigmatic peptide family. 
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